Résultats préliminaires d’une étude phase 1/2 évaluant la tolérance, la cinétique cellulaire et l’efficacité du rapcabtagene autoleucel (YTB323) un CAR-T ciblant le CD19 chez des patients avec un lupus érythémateux systémique sévère réfractaire (LESsr)

Autor: Amoura, Z., Choquet, S., Cortes-Hernandez, J., Barba, P., Alvaro-Gracia, J.M., Kwon, M., Weinmann-Menke, J., Wagner-Drouet, E., Fischer, O., Kovacs, B., Chaperon, F., Pearson, D., Kirsilä, T., Sean Lee, C.Y., Drakeford, C., Gergely, P., Cavalli, G., Shisha, T.

Publikováno v: In La revue de médecine interne December 2024 45 Supplement 2:A400-A401

Preclinical characterization of the Toll-like receptor 7/8 antagonist MHV370 for lupus therapy.

Autor: Hawtin S; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., André C; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Collignon-Zipfel G; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Appenzeller S; Department of Orthopedics, Rheumatology, and Traumatology, School of Medical Science, University of Campinas (UNICAMP), Campinas, 13083-887 São Paulo, Brazil., Bannert B; Department of Rheumatology, University Hospital Basel and University of Basel, 4031 Basel, Switzerland., Baumgartner L; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Beck D; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Betschart C; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Boulay T; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Brunner HI; Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA., Ceci M; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Deane J; Novartis Institutes for BioMedical Research, Novartis Pharma AG, La Jolla, CA 92121, USA., Feifel R; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Ferrero E; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Kyburz D; Department of Rheumatology, University Hospital Basel and University of Basel, 4031 Basel, Switzerland., Lafossas F; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Loetscher P; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Merz-Stoeckle C; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Michellys P; Novartis Institutes for BioMedical Research, Novartis Pharma AG, La Jolla, CA 92121, USA., Nuesslein-Hildesheim B; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Raulf F; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Rush JS; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Ruzzante G; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Stein T; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Zaharevitz S; Novartis Institutes for BioMedical Research, Novartis Pharma AG, La Jolla, CA 92121, USA., Wieczorek G; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Siegel R; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Gergely P; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Shisha T; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland., Junt T; Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4056 Basel, Switzerland. Electronic address: tobias.junt@novartis.com.

Publikováno v: Cell reports. Medicine [Cell Rep Med] 2023 May 16; Vol. 4 (5), pp. 101036.

Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial.

Autor: Smolen JS; Department of Rheumatology, Medical University of Vienna, Vienna, Austria., Cohen SB; Department of Rheumatology, Metroplex Clinical Research Center, Dallas, TX, USA., Tony HP; Department of Internal Medicine, Rheumatology/Clinical Immunology, University Hospital of Wuerzburg, Wuerzburg, Germany., Scheinberg M; Rheumatology Section, Orthopedic Department, Hospital Israelita Albert Einstein, Sao Paulo, Brazil., Kivitz A; Altoona Center for Clinical Research, Altoona Arthritis and Osteoporosis Center, Duncansville, PA, USA., Balanescu A; Sf. Maria Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania., Gomez-Reino J; Fundacion IDIS, Hospital Clinico Universitario, Santiago, Spain., Cen L; Biostatistics Biosimilars Analytics, Novartis Pharmaceuticals Corp, East Hanover, NJ, USA., Poetzl J; Biosimilar Clinical Development, Hexal AG, Holzkirchen, Germany., Shisha T; Translational Medicine, Novartis Institute of Biomedical Research, Basel, Switzerland., Kollins D; Biosimilar Clinical Development, Hexal AG, Holzkirchen, Germany.

Publikováno v: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2021 Jan 05; Vol. 60 (1), pp. 256-262.

MiR-574-5p activates human TLR8 to promote autoimmune signaling and lupus.

Autor: Wang, Tao^1,2 (AUTHOR), Song, Dan¹ (AUTHOR), Li, Xuejuan^3,4,5 (AUTHOR), Luo, Yu⁶ (AUTHOR), Yang, Dianqiang¹ (AUTHOR), Liu, Xiaoyan⁵ (AUTHOR), Kong, Xiaodan⁷ (AUTHOR), Xing, Yida⁷ (AUTHOR), Bi, Shulin¹ (AUTHOR), Zhang, Yan¹ (AUTHOR), Hu, Tao⁸ (AUTHOR), Zhang, Yunyun¹ (AUTHOR), Dai, Shuang¹ (AUTHOR), Shao, Zhiqiang¹ (AUTHOR), Chen, Dahan¹ (AUTHOR), Hou, Jinpao¹ (AUTHOR), Ballestar, Esteban^3,4,9 (AUTHOR), Cai, Jianchun¹⁰ (AUTHOR) jianchunfh2@sina.com, Zheng, Feng^3,4,5,11 (AUTHOR) fzheng@hsc.ecnu.edu.cn, Yang, James Y.^1,3,4 (AUTHOR) jamesyang@hsc.ecnu.edu.cn

Publikováno v: Cell Communication & Signaling. 4/8/2024, Vol. 22 Issue 1, p1-24. 24p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.